Blocking the signaling of leptin — a hormone involved in appetite regulation, motor function, and behavior — eased some Rett syndrome-like symptoms in a mouse model of the disease, a study found. Data showed that reducing leptin signaling either pharmacologically or genetically in male mice with Rett-like symptoms helped…
News
In mouse models of Rett syndrome, disease-related changes in the MeCP2 protein were linked to widespread disruptions in histones, proteins that help package DNA and regulate gene activity within cells. That’s according to the study, “Spatially resolved mapping of histones reveals selective neuronal response in Rett syndrome,” published…
Different mutations that cause Rett syndrome can have divergent effects on brain cell activity, a study found. The findings “hold promise for understanding mutation-specific mechanisms of Rett syndrome, and developing targeted mutation-specific therapeutics,” the researchers wrote. Through a series of experiments using cell models, the researchers identified biochemical strategies…
New recommendations support the use of the ready-to-use liquid formulation of trofinetide, sold as Daybue, as a first-line therapy for eligible people with Rett syndrome. A panel of 25 experts in managing the disease reached consensus on the recommendations. The panel endorsed early treatment initiation and an…
Daybue Stix, a powder formulation of Daybue (trofinetide), is now widely available for eligible people with Rett syndrome in the U.S., according to Acadia Pharmaceuticals, which markets both therapies. “The availability of DAYBUE STIX gives us an additional, flexible way to administer trofinetide, which allows us more…
Fenfluramine, an add-on medication already approved for certain types of epilepsy, may also help to reduce the frequency of hard-to-treat seizures in children with Rett syndrome, according to a new case series. The therapy specifically reduced seizures in three out of four girls with Rett syndrome who had…
Daybue Stix (trofinetide), a powder formulation of Daybue (trofinetide) approved to treat adults and children ages 2 and older with Rett syndrome, may be used interchangeably with the original strawberry-flavored, ready-to-use liquid formulation. That’s according to results from a Phase 1 study showing that a single 12,000…
MIT researchers have discovered that tiny blood vessels in the brains of people with Rett syndrome may be more permeable, or “leaky,” according to a new study. Using miniature models of blood vessel systems built with cells derived from Rett patients, the team found that this leakage was driven…
Modulating nerve cells to boost production of the mutant form of the MeCP2 protein that causes most cases of Rett syndrome may be a promising new therapeutic strategy for easing symptoms of the genetic condition. That’s according to new research in which U.S. scientists investigated this key protein using…
Acadia Pharmaceuticals will request a reexamination of a negative opinion recommending against approval of trofinetide, its oral therapy for Rett syndrome, in the European Union (EU). The therapy is already approved in the U.S., Canada, and Israel under the name Daybue. The opinion was issued by the Committee…
Recent Posts
- The day a famous actress joined girls with Rett syndrome in Washington
- Targeting leptin may ease some Rett-like symptoms, mouse study finds
- The stranger on the beach who performed an act of real charity
- Imagining the moments my late daughter would now be experiencing
- Rett mutations may disrupt DNA-packaging proteins in nerve cells
- Lamenting a broken memento of a big night out
- Study lays groundwork for mutation-specific Rett treatments
- The one question I wish my nonverbal child could answer
- The most difficult conversation I have ever had
- Experts recommend Daybue as first-line therapy for Rett syndrome